Understanding genetic causes of lymphoproliferative disorders in families
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
This study is trying to find out how genetics play a role in lymphoproliferative disorders, like Hodgkin's disease and lymphoma, by looking at families with a history of these cancers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Sex | All |
| Sponsor | Memorial Sloan Kettering Cancer Center Academic / other |
| Locations | 6 sites (Basking Ridge, New Jersey and 5 other locations) |
| Trial ID | NCT00582621 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the genetic factors contributing to lymphoproliferative disorders, including Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, and related cancers. Participants are identified based on their personal or family history of these conditions, allowing researchers to gather genetic data through blood, saliva, or buccal cell samples. The study seeks to enhance understanding of hereditary cancer risks and improve future prevention and treatment strategies.
Who should consider this trial
Good fit: Ideal candidates include individuals with a personal or family history of lymphoma, leukemia, or multiple myeloma.
Not a fit: Patients without a family history of lymphoproliferative disorders or those not diagnosed with related cancers may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better identification of genetic risks for lymphoproliferative disorders, enabling targeted prevention and treatment strategies for affected families.
How similar studies have performed: Other studies focusing on genetic factors in familial cancers have shown promise, suggesting that this approach could yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Individuals with a personal and/or family history of lymphoma or lymphoproliferative disease B-cell malignancies, or multiple myeloma referred for study participation, or MSK patients referred from to the MSKCC outpatient clinics of the Lymphoma, Multiple Myeloma, or Leukemia Services in the Department of Medicine in consultation for treatment who are found on routine history or through a Family History Questionnaire (FHQ) (Appendix A). Individuals who have relatives or members of successive generations of the family affected with Hodgkin's disease, non-Hodgkin's lymphoma, lymphoid leukemia, multiple myeloma other lymphoproliferative disease prostate or pancreatic cancers, or other conditions suggesting hereditary cancer at the discretion of the MSKCC Principal Investigator. Patients with lymphoma, associated with colon and renal cancer will be eligible for DNA storage through this protocol. Family members or probands with Hodgkin's disease who are women who received therapeutic irradiation for Hodgkin's disease" or who developed secondary cancers after Hodgkin's disease are also eligible for participation.
* The criteria for eligibility are broad because the ascertainment by the computerized FHQ does not allow for resolution of different types of lymphoma or different types of leukemia. Patient recall of this information is also imprecise. More accurate family history information will be obtained upon contact of family members and diagnoses will be verified by obtaining pathologic documentation. The spectrum of familial lymphoproliferative syndromes (LPS) may include all types of lymphoma as well as chronic lymphocytic leukemia. This is an additional reason to have a broad eligibility. Subset analysis will be performed on specific types of lymphoid neoplasms. DNA of patients with a family history of lymphoma who have consented to protocol 93-102 ("Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers") will also be eligible for inclusion in this study.
* Family members of probands including patients, sisters, brothers, halfbrothers and sisters, sons, daughters, grandparents, as well as aunts and uncles are also eligible. An effort will be made to ascertain all living affected and unaffected living relatives in the affected lineage. An emphasis will be on affected sibling pairs and both parents, if alive.
* As this study involves research that presents no greater than minimal risk to children (see Sec. 46.404 of Federal Regulations part 46), minors are also eligible for participation. The assent of any minor should be obtained before the patient is enrolled into this study, as well as the consent of the legal guardian.
Exclusion Criteria:
* N/A
Where this trial is running
Basking Ridge, New Jersey and 5 other locations
- Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey, United States (Recruiting)
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey, United States (Recruiting)
- Memorial Sloan Kettering Commack — Commack, New York, United States (Recruiting)
- Memorial Sloan Kettering Westchester — Harrison, New York, United States (Recruiting)
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (Recruiting)
- Memorial Sloan Kettering Rockville — Rockville Centre, New York, United States (Recruiting)
Study contacts
- Principal investigator: Kenneth Offit, MD — Memorial Sloan Kettering Cancer Center
- Study coordinator: Kenneth Offit, MD
- Phone: 646-888-4050
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.